AstraZeneca’s latest antibody to prevent Covid-19 hit on both of its primary endpoints in a large Phase 3 trial, the UK company said Thursday.
The preventive treatment known as sipavibart, which will likely serve as a successor to AstraZeneca’s Covid blockbuster drug Evusheld, reduced the incidence of symptomatic Covid-19 when compared to Evusheld or placebo among immunocompromised patients in the trial.
AstraZeneca said in a press release that the trial of 3,335 participants met both dual primary endpoints that looked at reducing the relative risk of symptomatic Covid and the relative risk of infections caused by variants not containing one specific mutation, known as the F456L mutation.
The trial, known as SUPERNOVA, demonstrated that sipavibart can potentially work “in an evolving variant landscape” as Covid cases in the trial were caused by several different variants, the company said.
Data will be presented at an upcoming medical meeting and AstraZeneca is in talks with regulators on potential approval pathways.
Evusheld, initially authorized in 2021, was cut off from use by the FDA in January 2023 as it was no longer effective against the circulating variants at the time. But the monoclonal antibody hauled in more than $2 billion in 2022, and the company also received an $855 million contract that same year from the US government to manufacture, distribute and store Evusheld.